Elgamal, Ola A.
Mehmood, Abeera
Jeon, Jae Yoon
Carmichael, Bridget
Lehman, Amy
Orwick, Shelley J.
Truxall, Jean
Goettl, Virginia M.
Wasmuth, Ronni
Tran, Minh
Mitchell, Shaneice
Lapalombella, Rosa
Eathiraj, Sudharshan
Schwartz, Brian
Stegmaier, Kimberly
Baker, Sharyn D.
Hertlein, Erin
Byrd, John C.
Funding for this research was provided by:
National Cancer Institute (R35 CA198183, T32 CA090223)
Ohio State University Pelotonia Foundation
Four Winds Foundation
D. Warren Brown Family Foundation
Article History
Received: 29 August 2019
Accepted: 7 November 2019
First Online: 28 January 2020
Ethics approval and consent to participate
: AML patient samples were obtained from The Ohio State University Comprehensive Cancer Center Leukemia Tissue Bank under an Institutional Review Board-approved protocol. All in vivo experiments were conducted after approval of The Ohio State University Institutional Animal Care and Use Committee.
: Not applicable
: S.E. and B.S. are current employees of ArQule, Inc. K.S. has previously consulted for Novartis and Rigel Pharmaceuticals and currently receives grant funding from Novartis. J.C.B. have or currently is consulting with Acerta, AstraZeneca, Pharmacyclics, and Jazz Pharmaceuticals. The other authors declare that they have no competing interests.